These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 21190978

  • 1. Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer.
    Lin CI, Du J, Shen WT, Whang EE, Donner DB, Griff N, He F, Moore FD, Clark OH, Ruan DT.
    J Clin Endocrinol Metab; 2011 Mar; 96(3):E554-65. PubMed ID: 21190978
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
    Zhao S, Wang Q, Li Z, Ma X, Wu L, Ji H, Qin G.
    J Exp Clin Cancer Res; 2015 Dec 04; 34():146. PubMed ID: 26637328
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation.
    Milewska M, Romano D, Herrero A, Guerriero ML, Birtwistle M, Quehenberger F, Hatzl S, Kholodenko BN, Segatto O, Kolch W, Zebisch A.
    PLoS One; 2015 Dec 04; 10(6):e0129859. PubMed ID: 26065894
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.
    Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, Holt EH, Kiseljak-Vassiliades K, Rhoden KJ, Tolaney S, Condouris S, Tallini G, Westra WH, Umbricht CB, Zeiger MA, Califano JA, Vasko V, Xing M.
    Int J Cancer; 2006 Nov 15; 119(10):2322-9. PubMed ID: 16858683
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
    Cao YM, Gu J, Zhang YS, Wei WJ, Qu N, Wen D, Liao T, Shi RL, Zhang L, Ji QH, Wang Y, Sun GH, Zhao YX, Wang YJ, Yu J, Zhu YX.
    Oncol Rep; 2018 Jan 15; 39(1):338-348. PubMed ID: 29115628
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Low expression of Mig-6 is associated with poor survival outcome in NSCLC and inhibits cell apoptosis via ERK-mediated upregulation of Bcl-2.
    Li Z, Qu L, Zhong H, Xu K, Qiu X, Wang E.
    Oncol Rep; 2014 Apr 15; 31(4):1707-14. PubMed ID: 24573418
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. MiR-96-5p promotes the proliferation, invasion and metastasis of papillary thyroid carcinoma through down-regulating CCDC67.
    Liu ZM, Wu ZY, Li WH, Wang LQ, Wan JN, Zhong Y.
    Eur Rev Med Pharmacol Sci; 2019 Apr 15; 23(8):3421-3430. PubMed ID: 31081096
    [Abstract] [Full Text] [Related]

  • 17. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
    Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P.
    Cancer Res; 2009 Nov 01; 69(21):8317-25. PubMed ID: 19861538
    [Abstract] [Full Text] [Related]

  • 18. MiR-145 inhibits the migration and invasion of papillary thyroid carcinoma cells through NF-κB pathway regulation.
    Chen G, Gao Y, Wang G, Dai G, Tong L.
    J Cell Biochem; 2020 Jun 01; 121(5-6):3325-3332. PubMed ID: 31907977
    [Abstract] [Full Text] [Related]

  • 19. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
    Zhang T, Shen X, Liu R, Zhu G, Bishop J, Xing M.
    Oncotarget; 2017 Jan 03; 8(1):900-914. PubMed ID: 27863429
    [Abstract] [Full Text] [Related]

  • 20. ZNRF3 is downregulated in papillary thyroid carcinoma and suppresses the proliferation and invasion of papillary thyroid cancer cells.
    Qiu W, Yang Z, Fan Y, Zheng Q.
    Tumour Biol; 2016 Sep 03; 37(9):12665-12672. PubMed ID: 27448298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.